208 related articles for article (PubMed ID: 12879633)
21. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.
Lau TK; Leachman DR; Lufschanowski R
Tex Heart Inst J; 2001; 28(2):142-5. PubMed ID: 11453128
[TBL] [Abstract][Full Text] [Related]
22. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
[TBL] [Abstract][Full Text] [Related]
23. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
[TBL] [Abstract][Full Text] [Related]
24. Preclinical and clinical pharmacology of cerivastatin.
Bischoff H; Heller AH
Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
[TBL] [Abstract][Full Text] [Related]
25. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
[TBL] [Abstract][Full Text] [Related]
26. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
27. Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.
Lucas RA; Weathersby BB; Rocco VK; Pepper JM; Butler KL
Pharmacotherapy; 2002 Jun; 22(6):771-4. PubMed ID: 12066968
[TBL] [Abstract][Full Text] [Related]
28. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
29. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
30. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
31. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
[TBL] [Abstract][Full Text] [Related]
32. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
33. Cerivastatin and reports of fatal rhabdomyolysis.
Staffa JA; Chang J; Green L
N Engl J Med; 2002 Feb; 346(7):539-40. PubMed ID: 11844864
[No Abstract] [Full Text] [Related]
34. [Characteristics of a statine of the most recent generation].
Notarbartolo A; Barbagallo CM
Ital Heart J Suppl; 2001 Mar; 2(3):230-4. PubMed ID: 11307781
[TBL] [Abstract][Full Text] [Related]
35. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
[TBL] [Abstract][Full Text] [Related]
36. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
Tamraz B; Fukushima H; Wolfe AR; Kaspera R; Totah RA; Floyd JS; Ma B; Chu C; Marciante KD; Heckbert SR; Psaty BM; Kroetz DL; Kwok PY
Pharmacogenet Genomics; 2013 Jul; 23(7):355-64. PubMed ID: 23652407
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyolysis and HMG-CoA reductase inhibitors.
Omar MA; Wilson JP; Cox TS
Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
[TBL] [Abstract][Full Text] [Related]
38. [Myotoxicity and rhabdomyolisis due to statins].
Banga JD
Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
[TBL] [Abstract][Full Text] [Related]
39. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
Sica DA; Gehr TW
Curr Opin Nephrol Hypertens; 2002 Mar; 11(2):123-33. PubMed ID: 11856903
[TBL] [Abstract][Full Text] [Related]
40. [Adverse effects of statins].
Andréjak M; Gras V; Massy ZA; Caron J
Therapie; 2003; 58(1):77-83. PubMed ID: 12822204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
